A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-418 in Healthy Female Subjects
Phase of Trial: Phase I
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs TAK 418 (Primary)
- Indications Inborn genetic disorders
- Focus Adverse reactions
- Sponsors Takeda
- 02 May 2019 Status changed from active, no longer recruiting to discontinued.
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2018 Status changed from not yet recruiting to recruiting.